Titanium dioxide

Drug profile

Key facts

Titanium dioxide is a drug catalogued in DrugCentral. It was first approved by the FDA in 2006.

• Molecular formula: O2Ti; molecular weight 79.86 g/mol.

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2006-10-05	FDA	—	LOREAL USA

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Macular degeneration	1102.5
Chronic sinusitis	407.0
Vaginal flatulence	365.0
Paraesthesia oral	362.5
Female genital tract fistula	353.3
Procedural pain	339.3
Radiculopathy	318.2
Proctitis	318.0
Vaginal discharge	317.5
Joint dislocation	208.9
Oral candidiasis	207.0
Joint stiffness	181.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Titanium dioxide is on its molecule page.

• Molecular formula: O₂Ti
• Molecular weight: 79.86 g/mol
• CAS number: 13463-67-7
• InChIKey: GWEVSGVZZGPLCZ-UHFFFAOYSA-N
• PubChem CID: 26042

O=[Ti]=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

When was Titanium dioxide first approved?

Titanium dioxide was first approved by the FDA in 2006.

What is the chemical formula of Titanium dioxide?

Titanium dioxide has the molecular formula O2Ti and a molecular weight of 79.86 g/mol.

Sources

• DrugCentral drug card 4237 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201136 — compound record and bioactivity
• PubChem CID 26042 — chemical identifiers
• DrugBank DB09536 — drug record
• FDA UNII 15FIX9V2JP — substance identity
• DailyMed: FDA labels for Titanium dioxide — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.